- Trial phase
- Filed/510(k) submission
- Time to market
- NXT-41 (base matrix) clearance decision expected Q4 2026 (within ~2 months). NXT-41x (antibiotic-eluting) clearance expected Q2 2027, with first full year of commercial launch targeted for 2028.
- Why 7/10
- The next hard, dated catalyst is the FDA 510(k) clearance decision for NXT-41 (base biologic matrix) expected in Q4 2026 (by December 31, 2026), roughly 2 months away. NXT-41x is the company's lead asset and drives essentially the entire investment thesis after the company sold its BioEnvelope business to Boston Scientific for $88M and its SimpliDerm business. ImpactScore 7 reflects a dated binary within ~6 months on the company's lead asset that drives most of the thesis, though NXT-41 is the precursor product (base matrix without drug) and the bigger value driver (NXT-41x clearance) is expected Q2 2027.
Watch for the FDA 510(k) clearance decision on NXT-41 (base biologic matrix), expected by end of Q4 2026 (any day now through December). A clearance would validate the platform and clear the path for NXT-41x submission. The bigger catalyst is NXT-41x clearance expected Q2 2027, which would open the $1.5B breast reconstruction market. The company is fully funded through launch, removing near-term dilution risk. However, as a micro-cap single-product story, any regulatory delay or negative FDA feedback would hit the stock hard.
Price Chart
Executive Summary
Elutia (NASDAQ: ELUT) is a micro-cap biotech that has refocused entirely on its NXT-41/NXT-41x platform for infection prevention in breast reconstruction surgery. NXT-41 is a biologic surgical matrix (tissue scaffold) submitted for FDA 510(k) clearance with a decision expected by end of Q4 2026. NXT-41x adds rifampin and minocycline antibiotics to the matrix and is the company's true value driver, with FDA submission planned for Q4 2026 and clearance expected Q2 2027. The company has raised ~$26M in non-dilutive capital (Avenue Capital loan, SimpliDerm sale, Boston Scientific escrow payment) and says it is fully funded through NXT-41x launch in 2028. The stock trades around $0.84 with a 52-week range of $0.50-$1.39, reflecting both the binary nature of the upcoming FDA decisions and the company's transformation from a diversified biologics business into a single-product story.
How It Works
NXT-41 is a biologic surgical matrix (a decellularized tissue scaffold) used in breast reconstruction surgery to support tissue healing. NXT-41x is the enhanced version that adds two antibiotics (rifampin and minocycline) that slowly release from the matrix to prevent post-surgical infections. Think of it as a temporary, absorbable mesh that both supports the surgical site and actively fights bacteria. Post-operative infection rates in complex plastic surgery are reported as high as 23%, making this a significant unmet need.
Trial Status
NXT-41 (base biologic matrix without drug) was submitted to the FDA as a 510(k) clearance application and is under active review. The company expects a clearance decision in Q4 2026 (by end of December 2026). NXT-41x (antibiotic-eluting version) has completed a key performance study with positive results supporting submission; the company plans to submit it to the FDA in Q4 2026, with clearance anticipated in Q2 2027 (first half of 2027).
The Two-Sided Case
Upcoming Catalysts
- FDA 510(k) clearance decision for NXT-41 (base biologic matrix) expected Q4 2026 (by end of December 2026)
- FDA submission of NXT-41x (antibiotic-eluting version) planned for Q4 2026
- FDA 510(k) clearance decision for NXT-41x expected Q2 2027 (first half of 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ELUTIA INC. 8-K ELUT ·Originating report